Objective. Study on the pharmacodynamic basis and mechanism of Huanglian Jiedu Decoction against atopic dermatitis (AD). Methods. Based on network pharmacology, the targets of Huanglian Jiedu Decoction and AD were screened by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), SwissTargetPrediction databases, and the database of Online Mendelian Inheritance in Man (OMIM), Therapeutic Targets Database (TTD) and the Comparative Toxicogenomics Database (CTD); then, “chemical composition-target-related pathway-disease target” network graph of Huanglian Jiedu Decoction against AD was constructed by using STRING and Cytoscape software. In combination with in vitro experiments, the levels of IL-4, IL-6, and IL-10 in T cells were determined by ELISA; the pharmacodynamic basis and mechanism of Huanglian Jiedu Decoction against AD were preliminarily explored. Results. 81 active ingredients in Huanglian Jiedu Decoction were screened by network pharmacology, 31 of which were related to atopic dermatitis, corresponding to 12 target proteins. A total of 14 pathways were obtained by KEGG pathway analysis, and 8 were associated with atopic dermatitis. Compared with the control group, 20 and 40 µg/ml of Huanglian Jiedu Decoction could significantly reduce the contents of IL-4, IL-6, and IL-10 in T lymphocytes of mice with atopic dermatitis (). Conclusion. Huanglian Jiedu Decoction can act against AD by multicomponent, multitarget, and multichannel mode of action.

中文翻译：

---

黄连解毒汤治疗特应性皮炎的研究

目标。黄连解毒汤对特应性皮炎的药效基础和作用机理研究。方法。在网络药理学的基础上，通过中药系统药理数据库和分析平台（TCMSP），SwissTargetPrediction数据库，在线孟德尔遗传人类数据库（OMIM），治疗目标数据库（TTD）筛选出黄连解毒汤和AD的靶标。 ）和比较毒物基因组学数据库（CTD）；然后利用STRING和Cytoscape软件构建了黄连解毒汤抗AD的“化学成分-靶标相关途径-疾病靶标”网络图。结合体外实验，采用ELISA法测定T细胞中IL-4，IL-6和IL-10的水平。初步探讨了黄连解毒汤对AD的药理基础和作用机理。结果。通过网络药理学筛选了黄连解毒汤中的81种有效成分，其中31种与特应性皮炎有关，对应于12种靶蛋白。通过KEGG通路分析获得的通路共有14条，其中8条与特应性皮炎有关。与对照组相比，黄连解毒汤20和40  µg / ml可以显着降低特应性皮炎小鼠T淋巴细胞中IL-4，IL-6和IL-10的含量（）。 结论。黄连解毒汤可通过多组分，多靶点和多通道作用方式对抗AD。